Literature DB >> 23242013

[Antipsychotics for treatment of neuropsychiatric disorders in dementia].

H-J Gertz1, G Stoppe, B Müller-Oerlinghausen, L G Schmidt, C Baethge, C Hiemke, K Lieb, T Bschor.   

Abstract

Antipsychotics, when used to treat neuropsychological symptoms associated with dementia, are associated with low effectiveness but a high risk of side effects. Some of these unwanted effects are severe and include an increased rate of cerebrovascular events and increased mortality. Although neuropsychiatric symptoms are frequently associated with dementia, it appears that antipsychotics are often used without clear indications and for too long time periods. Antipsychotics should be used only when all non-pharmacological strategies have failed. A clear definition of the treatment target in advance and a continuous monitoring of the therapy are mandatory.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23242013     DOI: 10.1007/s00115-012-3693-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  21 in total

1.  [Determinants of psychotropic drug utilization in homes for the elderly and in nursing homes].

Authors:  G Stelzner; S G Riedel-Heller; A Sonntag; H Matschinger; A Jakob; M C Angermeyer
Journal:  Z Gerontol Geriatr       Date:  2001-08       Impact factor: 1.281

2.  Psychotropic medication use in Swiss nursing homes.

Authors:  I Lustenberger; B Schüpbach; A von Gunten; U Mosimann
Journal:  Swiss Med Wkly       Date:  2011-10-04       Impact factor: 2.193

Review 3.  The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.

Authors:  C Ballard; J Waite
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

4.  [Antipsychotic treatment of dementia after publication of new risks].

Authors:  Markus Wittmann; Helmut Hausner; Göran Hajak; Ekkehard Haen
Journal:  Psychiatr Prax       Date:  2009-09-01

5.  Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.

Authors:  Lon S Schneider; Karen Dagerman; Philip S Insel
Journal:  Am J Geriatr Psychiatry       Date:  2006-03       Impact factor: 4.105

6.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications.

Authors:  Philip S Wang; Sebastian Schneeweiss; Jerry Avorn; Michael A Fischer; Helen Mogun; Daniel H Solomon; M Alan Brookhart
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

7.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

8.  The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.

Authors:  Clive Ballard; Maria Luisa Hanney; Megan Theodoulou; Simon Douglas; Rupert McShane; Katja Kossakowski; Randeep Gill; Edmund Juszczak; Ly-Mee Yu; Robin Jacoby
Journal:  Lancet Neurol       Date:  2009-01-08       Impact factor: 44.182

9.  The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study.

Authors:  B C Jost; G T Grossberg
Journal:  J Am Geriatr Soc       Date:  1996-09       Impact factor: 5.562

10.  Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial.

Authors:  Bettina S Husebo; Clive Ballard; Reidun Sandvik; Odd Bjarte Nilsen; Dag Aarsland
Journal:  BMJ       Date:  2011-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.